Organon & Co. Files 8-K for Other Events

Ticker: OGN · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1821825

Organon & CO. 8-K Filing Summary
FieldDetail
CompanyOrganon & CO. (OGN)
Form Type8-K
Filed DateDec 23, 2024
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 8-k, disclosure

Related Tickers: OGN

TL;DR

Organon filed an 8-K for 'Other Events' on 12/23, event date 12/20. Details TBD.

AI Summary

Organon & Co. filed an 8-K on December 23, 2024, reporting an event that occurred on December 20, 2024. The filing pertains to 'Other Events' and does not specify any material agreements, acquisitions, or financial changes in the provided text.

Why It Matters

This filing indicates Organon & Co. is reporting an event not covered by other standard 8-K categories, requiring investors to look for further disclosures or context.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure without immediate financial or operational implications mentioned.

Key Players & Entities

FAQ

What specific event is Organon & Co. reporting under 'Other Events'?

The provided text of the 8-K filing does not specify the nature of the 'Other Events' being reported.

When did the event reported in the 8-K occur?

The earliest event reported occurred on December 20, 2024.

What is the filing date of this 8-K?

This 8-K was filed on December 23, 2024.

What is Organon & Co.'s primary business classification?

Organon & Co. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.

Where are Organon & Co.'s principal executive offices located?

Organon & Co.'s principal executive offices are located at 30 Hudson Street, Floor 33, Jersey City, NJ 07302.

Filing Stats: 403 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2024-12-23 06:01:08

Key Financial Figures

Filing Documents

01. Other Events

Item 8.01. Other Events On December 20, 2024, following the previously-announced resignation of Martha E. McGarry from the Board of Directors (the " Board ") of Organon & Co., the Board reduced its size to eleven members, which eliminated the vacancy created by Ms. McGarry's resignation. Exhibit No. Description 104 The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Organon & Co. By: /s/ Kirke Weaver Name: Kirke Weaver Title: General Counsel & Corporate Secretary Dated: December 23, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing